

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 July 2023 (27.07.2023)



(10) International Publication Number
WO 2023/141247 A2

- (51) **International Patent Classification:**
C12N 15/85 (2006.01) A61K 31/712 (2006.01)
- (21) **International Application Number:**
PCT/US2023/011200
- (22) **International Filing Date:**
20 January 2023 (20.01.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/301,454 20 January 2022 (20.01.2022) US
63/328,629 07 April 2022 (07.04.2022) US

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(71) **Applicant: ALEXION PHARMACEUTICALS, INC.** [US/US]; 121 Seaport Boulevard, Boston, Massachusetts 02210 (US).

(72) **Inventors; and**

(71) **Applicants: DUDEK, Henryk T.** [US/US]; 75 Hayden Avenue, Lexington, Massachusetts 02421 (US). **PARK, Jihye** [KR/US]; 75 Hayden Ave., Lexington, Massachusetts 02421 (US). **BROWN, Bob Dale** [US/US]; 75 Hayden Ave., Lexington, Massachusetts 02421 (US). **LAI, Chengjung** [US/US]; 75 Hayden Ave., Lexington, Massachusetts 02421 (US). **KIM, SungKwon** [KR/US]; c/o Alexion Pharmaceuticals, Inc., 121 Seaport Boulevard, Boston, Massachusetts 02210 (US). **BEASLEY, Kathleen Nicole** [US/US]; c/o Alexion Pharmaceuticals, Inc., Boston, Massachusetts 02210 (US).

(72) **Inventors: LASARO, Melissa**; c/o Alexion Pharmaceuticals, Inc., 121 Seaport Boulevard, Boston, Massachusetts 02210 (US). **MCKNIGHT, Susan Faas**; 14 Stonewood Drive, Old Lyme, Connecticut 06371 (US).

(74) **Agent: HLAVKA, Christine M.**; Alexion Pharmaceuticals, Inc., Attn.: Legal - Intellectual Property Dept., 100 College Street, New Haven, Connecticut 06510 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) **Title:** COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT FACTOR B

(57) **Abstract:** Described herein are oligonucleotides (e.g., RNAi oligonucleotides) containing sense and antisense strands for targeting complement factor B (CFB) mRNA. The RNAi oligonucleotide may be used to inhibit CFB expression, levels, and/or activity in a cell. Also, described herein are methods for using an oligonucleotide (e.g., an RNAi oligonucleotide) for the prophylaxis or treatment of a disease, disorder, or condition mediated by complement pathway activation or dysregulation.

WO 2023/141247 A2